Biogen job cuts may undermine Cambridge expansion; EMA director lays out 5-year plan;

@FiercePharma: India's Dr. Reddy's responds to U.S. FDA warning letter. FiercePharmaAsia article | Follow @FiercePharma

@CarlyHFierce: I'm sorry, but you had 20 years to brainstorm on this, and you came up with "Dengvaxia?" | Follow @CarlyHFierce

> Biogen ($BIIB) may be backing off plans to expand in the Boston area after announcing plans to cut 11% of its workforce. Story

> Biotech Alnylam Pharmaceuticals ($ALNY) threw down a gauntlet to Alexion ($ALXN), laying out plans to bring to market a drug that would challenge Alexion's orphan drug Soliris, sometimes called the worlds' most expensive drug. Story

> EMA Executive Director Guido Rasi laid out a 5-year plan for drug oversight in Europe which includes faster drug approvals, accomplished without compromising quality. Story

> Indiana-based Eli Lilly ($LLY) has made a $30,000 grant to help fund 100 drug disposal sites at pharmacies in the state. More

Medical Device News

@FierceMedDev: ICYMI yesterday: Chemotherapy cooling cap to reduce hair loss for breast cancer patients gets FDA nod. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Edwards grabs option to acquire transcather mitral valve replacement startup. Article | Follow @VarunSaxena2

@EmilyWFierce: Cornell scientists create first litter of puppies through in vitro fertilization. FierceAnimalHealth story | Follow @EmilyWFierce

> Edwards bets on treating degenerative regurgitation via mitral repair with Harpoon investment. More

> Bloomberg: Embattled Theranos CEO continues to beat the 'transparency' drum. Story

> MicroTransponder reels in $5.5M for stroke neurostimulation device. Article

Biotech News

@FierceBiotech: With Roche in the rearview mirror, Constellation Pharma grabs $55M round. Article | Follow @FierceBiotech

@JohnCFierce: Now we get to see if Merck KGaA can swing big and actually hit the ball. Article | Follow @JohnCFierce

> After failing a PhII/III, Raptor steers Huntington's drug into a pivotal trial. Article

> Puma's once-vaunted cancer drug dogged by side effects in Phase II results. Item

> In a win for NYC, gut-brain biotech Kallyope launches with $44M. News

> FierceBiotech Radio on the burning hole in Gilead's $25B pocket and AbbVie's future in hematology. More | Subscribe

CRO News

> Icon buys a trial site network with an eye on patient data. News

> WuXi and PRA break up their Chinese joint venture. More

> Charles River digs into Parkinson's R&D with Fox Foundation in tow. Story

> Quintiles extends its R&D hand-holding service to biopharmas large and small. Report

> Restructured AMRI cuts the ribbon on a drug discovery hub. Article

Pharma Manufacturing News

> Sucampo finalizes $278M deal of R-Tech Ueno's manufacturing plant in Japan. News

> Axxess Pharma has tapped SDC Nutrition for product manufacturing. Report

> FDA issues import alert on Pan Pharma, ramping up its pressure on the India drugmaker. Story

> Eli Lilly to manufacture human and animal drugs in separate facilities. Article

> Study: Shortfall of skilled inspectors in India hinders pharma industry. Item

Pharma Asia News

> WuXi and PRA Health amend ties in China. Item

> U.S. FDA files import alert on India's Pan Drugs. More

> China aims precision medicine plans at chronic diseases. Report

> Bangladesh again noted for dominant domestic drug manufacture. Story

> Takeda inks pact with Cour for celiac disease therapy via nanoparticles. Article

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.